Shares of AstraZeneca plc (LON:AZN) have received an average rating of “Hold” from the twenty-two research firms that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is GBX 4,804.35 ($62.05).

A number of analysts recently commented on the company. J P Morgan Chase & Co reiterated a “neutral” rating on shares of AstraZeneca plc in a research report on Friday. Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc in a research report on Thursday. Natixis upgraded AstraZeneca plc from a “neutral” rating to a “buy” rating and upped their price objective for the company from GBX 5,000 ($64.57) to GBX 5,738 ($74.11) in a research report on Wednesday. Deutsche Bank AG reiterated a “buy” rating and set a GBX 5,300 ($68.45) price objective on shares of AstraZeneca plc in a research report on Tuesday. Finally, Liberum Capital reiterated a “buy” rating and set a GBX 4,800 ($61.99) price objective on shares of AstraZeneca plc in a research report on Tuesday.

Shares of AstraZeneca plc (LON AZN) opened at 4790.00 on Friday. The stock’s market cap is GBX 60.64 billion. The company has a 50-day moving average price of GBX 4,593.39 and a 200 day moving average price of GBX 4,871.66. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00.

The firm also recently declared a dividend, which will be paid on Monday, September 11th. Investors of record on Thursday, August 10th will be paid a dividend of GBX 68.90 ($0.89) per share. This represents a dividend yield of 1.35%. The ex-dividend date is Thursday, August 10th.

In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The stock was purchased at an average cost of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/09/astrazeneca-plc-azn-receives-average-recommendation-of-hold-from-brokerages.html.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.